GSK Wins U.S. Approval for Hibsago, but Monitoring Burden Tests £2.2 Billion Sales Case
U.S. approval moves GSK's hepatitis B therapy from regulatory risk to commercial execution. Functional-cure results support a large opportunity, but boxed warnings and frequent laboratory checks may slow adoption.
GSK has won U.S. approval for Hibsago, its 24-week treatment for selected adults with chronic hepatitis B, giving the company a chance to replace indefinite antiviral therapy with a finite course. Jefferies kept its buy rating and 2,500 pence target, arguing that the approved population supports its £2.2 billion peak-sales estimate. That target was 34% above the 1,868.5 pence closing price used in the broker's October 21 note.
The approval covers adults without cirrhosis who meet specified treatment and viral-antigen criteria. Hibsago, also known as bepirovirsen, is administered for 24 weeks. After the first dose, eligible patients can give subsequent doses to themselves. GSK's two Phase 3 studies reported functional-cure rates of 20% and 19%, versus no responders in the placebo groups. A functional cure can allow some patients to stop long-term antiviral therapy, which is the treatment's clearest commercial advantage.
The label also explains why approval does not settle the investment case. Hibsago carries a boxed warning for hepatic flares, meaning worsening liver inflammation, and for thrombocytopenia, a reduction in blood platelets that can increase bleeding risk. Patients need weekly platelet tests throughout treatment, weekly liver-function tests for the first 12 weeks and tests every other week through week 24. Kidney function must be checked at least every other week, with more frequent monitoring when renal function deteriorates.
Those requirements could concentrate early use in specialist liver centers and limit the number of patients a clinic can manage. They may also deter physicians or patients who see stable long-term antivirals as simpler, even if those drugs do not offer the same prospect of a functional cure.
The U.S. decision therefore shifts the question from whether Hibsago can reach the market to how quickly GSK can build the testing, training and reimbursement support needed for routine use. Future combinations that raise cure rates or broaden the eligible population could expand the opportunity, but the first measurable evidence will be prescription uptake and persistence under the approved monitoring schedule.